<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clusterin expression has been reported to be characteristic of systemic anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and usually negative in cutaneous anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> as well as other <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types </plain></SENT>
<SENT sid="1" pm="."><plain>We surveyed clusterin expression using immunohistochemical methods in 266 cases of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> to further assess the diagnostic utility of this marker </plain></SENT>
<SENT sid="2" pm="."><plain>Clusterin immunostaining was observed in 40 of 49 (82%) systemic anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 12 of 29 (41%) cutaneous anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Clusterin also was expressed in 5 of 43 (12%) diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (4 of 5 CD30+), 1 of 14 (7%) peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 1 of 32 (3%) cases of nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, and 1 case of <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e> in large cell transformation </plain></SENT>
<SENT sid="4" pm="."><plain>Clusterin was negative in <z:hpo ids='HP_0000001'>all</z:hpo> other <z:hpo ids='HP_0002664'>neoplasms</z:hpo> assessed including follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of <z:hpo ids='HP_0000001'>all</z:hpo> grades (n = 24), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 13), marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 12), precursor T-cell or B-cell lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 10), <z:e sem="disease" ids="C0152266" disease_type="Neoplastic Process" abbrv="MCHL">mixed cellularity Hodgkin's disease</z:e> (n = 8), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 7), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 7), <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e> (n = 4), nodular lymphocyte predominant <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (n = 3), lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005508'>Waldenstrom macroglobulinemia</z:hpo> (n = 2), and <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> (n = 2) </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that clusterin is a marker of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and that addition of clusterin to antibody panels designed to distinguish systemic anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> from classical <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> is useful </plain></SENT>
<SENT sid="6" pm="."><plain>However, clusterin is also positive in a substantial subset of cutaneous anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, a smaller subset of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and rarely in cases of peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
</text></document>